Janssen R&D Ireland, of Cork, Ireland, and Medivir AB, of Huddinge, Sweden, said results from the phase II COSMOS study were published in The Lancet, demonstrating that 92 percent of genotype 1 chronic hepatitis C virus adult patients treated with simeprevir, an NS3/4A protease inhibitor, in combination with sofosbuvir (Gilead Sciences Inc.), achieved sustained virologic response 12 weeks after the end of treatment, including those patients with compensated cirrhosis and prior null response to treatment with pegylated interferon and ribavirin.